Teva Pharmaceutical Industries Limited
TEVA evidence brief
What we can confirm
- BioSniper Score:
- 6.2 / 10
- Market Cap:
- $42.73B
- Lead Asset:
- airduo respiclick (Approved)
What it means
What to watch
Prepared research question
What matters most for TEVA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TEVA
Teva Pharmaceutical Industries Ltd. (TEVA) is a global pharmaceutical company executing a 'Pivot to Growth' strategy, balancing a strong generics and biosimilars business with advancing a late-stage innovative pipeline including olanzapine LAI and duvakitug.
Key risk: Net loss position
BioSniper Score
Based on 6 of 6 signals
Market Cap
$42.73B
Cash Runway
—
Lead Asset
airduo respiclick (Approved)Next Catalyst
Patent_Expiry · Mar 17, 2042Financial data as of Jun 30, 2026.
Tracking 32 pipeline candidates · 33 clinical trials · 1 catalyst · 62 FDA decisions for Teva Pharmaceutical Industries Limited.
Teva Pharmaceutical Industries Ltd. (TEVA) is a global pharmaceutical company executing a 'Pivot to Growth' strategy, balancing a strong generics and biosimilars business with advancing a late-stage innovative pipeline including olanzapine LAI and duvakitug.
- Cash & equivalents of $3,655.0M as of 2026-06-30 [sec].
- Total revenue of $4,142.0M and net income of -$576.0M as of 2026-06-30 [sec].
- Filed an NDA for olanzapine LAI in December 2025 and initiated Phase 3 trials for duvakitug (anti-TL1A) in October 2025 [sec · filed 2026-03-31].
- Launched biosimilars SELARSDI® (ustekinumab-aekn) and EPYSQLI® (eculizumab-aagh) in the U.S. in 2025 [sec · filed 2026-03-31].
- Teva Transformation programs expected to generate ~$700 million of net savings through 2027; achieved targeted savings for 2025 [sec · filed 2026-03-31].
What works
- Strong growth in key innovative products: AUSTEDO grew 34% globally, AJOVY grew 30% globally, and UZEDY grew 63% in the U.S. compared to 2024 [sec · filed 2026-03-31].
- Advancing late-stage pipeline with multiple key readouts expected in 2026-2027, including olanzapine LAI NDA filing and Phase 3 initiation for duvakitug [sec · filed 2026-03-31].
- Biosimilars portfolio progressing with recent U.S. launches and late-stage pipeline for Prolia®, Xgeva®, Eylea®, Simponi® and Simponi Aria® [sec · filed 2026-03-31].
- Disciplined cost management with Teva Transformation programs targeting ~$700 million net savings through 2027, with 2025 targets achieved [sec · filed 2026-03-31].
What to weigh
- Net income of -$576.0M as of 2026-06-30 indicates ongoing net losses [sec].
- Patent expiry for RISPERIDONE (NDA213586) scheduled for 2042-03-17, which may impact future revenue from related products [catalyst].
- Reliance on external funding partnerships and strategic collaborations for pipeline development, which may introduce dependency risks [sec · filed 2026-03-31].
- Generics business faces pricing pressures and competition, though the company continues to optimize its portfolio [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
Olanzapine LAI NDA filing
“filing of a New Drug Application ("NDA") for olanzapine LAI in December 2025”
SEC filings · March 31, 2026
Duvakitug Phase 3 initiation
“Phase 3 programs for duvakitug (anti-TL1A) were initiated in October 2025”
SEC filings · March 31, 2026
Catalyst timeline
- 2042-03-17 · Patent_Expiry · RISPERIDONE — Patent expiry for NDA213586 may open market to generic competition, potentially impacting revenue from risperidone-based products.
Risks & what to watch (4)›
Key risks
- Net loss position — Net income of -$576.0M as of 2026-06-30 indicates ongoing financial losses [sec].
- Patent expiry exposure — RISPERIDONE patent expiry on 2042-03-17 may affect future revenue from related products [catalyst].
- Pipeline dependency — Reliance on external partnerships for pipeline development may create execution risks [sec · filed 2026-03-31].
- Generics market pressure — Generics business faces pricing and competition challenges, requiring ongoing portfolio optimization [sec · filed 2026-03-31].
What to watch
- Progress of olanzapine LAI NDA review and potential FDA decision [sec · filed 2026-03-31].
- Phase 3 readouts for duvakitug in ulcerative colitis and Crohn's disease expected in 2026-2027 [sec · filed 2026-03-31].
- Achievement of Teva Transformation net savings targets through 2027 [sec · filed 2026-03-31].
- Biosimilar launches and regulatory approvals for Prolia®, Xgeva®, Eylea®, Simponi® and Simponi Aria® [sec · filed 2026-03-31].
Sources: SEC filings · Generated October 12, 2026 · How we verify sources →
Run Teva Pharmaceutical Industries Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Teva Pharmaceutical Industries Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 4.14 · 0% dilution
Lead: Approved
32 candidates
1 upcoming, next in ~5633d
0 buys · 18 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
647
Total value held
$16.90B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 65,136,464 | $1.96B |
| phoenix financial ltd. | 42,777,414 | $1.29B |
| menora mivtachim holdings ltd. | 39,626,383 | $1.19B |
| wcm investment management, llc | 40,820,600 | $1.16B |
| migdal insurance & financial holdings ltd. | 37,902,212 | $1.14B |
| fmr llc | 33,132,795 | $998.0M |
| lingotto investment management llp | 27,770,857 | $836.5M |
| state street corp | 17,790,020 | $535.8M |
| rubric capital management lp | 15,250,000 | $459.3M |
| altshuler shaham ltd | 11,463,621 | $334.6M |
Showing top 10 of 647 institutional holders of Teva Pharmaceutical Industries Limited. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.6%
- Days to cover
- 5.2
- Shares short
- 29,736,398
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TEVA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Ltd. (TEVA) is a global pharmaceutical company executing a 'Pivot to Growth' strategy, balancing a strong generics and biosimilars business with advancing a late-stage innovative pipeline including olanzapine LAI and duvakitug.
What is Teva Pharmaceutical Industries Limited's lead drug candidate?
Teva Pharmaceutical Industries Limited's most advanced tracked candidate is airduo respiclick (Approved).
What is Teva Pharmaceutical Industries Limited's next catalyst?
Teva Pharmaceutical Industries Limited's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA213586" — expected March 17, 2042.
Who is the CEO of Teva Pharmaceutical Industries Limited?
Mr. Richard D. Francis is the chief executive officer of Teva Pharmaceutical Industries Limited (TEVA).
Where is Teva Pharmaceutical Industries Limited headquartered?
Teva Pharmaceutical Industries Limited (TEVA) is headquartered in Tel Aviv-Yafo, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.